Sleeping Bruxism Treatment Market Research Report - Forecast till 2027

Sleeping Bruxism Treatment Market Research Report: Information by Type (Primary Bruxism and Secondary Bruxism), Diagnosis (Clinical Examination, X-rays, Electromyographic Methods and Polysomnography), Treatment Type [Dental Approaches (Mouth Guard and NTI-TSS Device) and Medication (Muscle Relaxants, Botox Injections and Anti-anxiety Drugs)], Cause [Obstructive Sleep Apnea, Gastroesophageal Reflux Disease (GERD), Malocclusion and Sleep Paralysis], Patient Type [Pediatric and Adult (Male and Female)] - Forecast till 2027

ID: MRFR/Pharma/3979-CR | February 2021 | Region: Global | 151 pages

Sleeping Bruxism Treatment Market Overview

The CAGR for the Sleeping Bruxism Treatment Market is 6.7% in the forecast period. The Sleeping Bruxism Treatment Market valuation will reach a mark of USD 638.2 Million in 2023. The Market shows strong trends of growth in the forecast period. In this Market report, all the details of the Market forecast are discussed.

The condition of Sleep Bruxism is one where the patient grinds his teeth during sleep. Bruxism is something that happens during the day. However, it also happens involuntarily in sleep too. The condition of sleep bruxism is more serious because the patient is not aware at that time. The patient applies a lot of force on his teeth and jaw during such episodes. This inflicts a lot of damage to the teeth and jaw. The patient cannot control the force he puts on his teeth and jaw. Therefore, it becomes necessary to treat the symptoms of sleep bruxism. The Sleeping Bruxism Treatment Industry deals with the various treatment and care approaches for sleep bruxism recovery.

People who use tobacco, alcohol, or other intoxicating substances are more prone to Sleeping Bruxism. The people who take antidepressants also go through such conditions. People who smoke cigarettes and regularly drink caffeine are also prone to sleeping bruxism. Since a lot of people consume such substances, sleep bruxism is pretty common today. Therefore, there is a huge opportunity for the Sleeping Bruxism Treatment Industry to step up.

The instances of sleep bruxism are not persistent throughout the night for the patients. Instead, people suffer episodes of Sleep Bruxism at times. However, the force of grinding is so high that the person suffers much damage within a few minutes.

COVID 19 Analysis

The COVID 19 pandemic and bruxism, in general, are highly connected. The COVID 19 pandemic causes a lot of stress for different people. The study of people’s behavior shows that instances of stress as well as factors of stress have increased for the population. This is a direct impact of the socioeconomic disruption caused by the pandemic. People have turned towards antidepressants and sleeping pills to induce sound sleep. However, such substances can also result in sleeping bruxism.

Therefore, instances of sleeping bruxism have increased over the span of the pandemic. This creates a window of growth for the Sleeping Bruxism Treatment Market. However, the highest focus of the healthcare industry has been on treating COVID 19 infections. This means that sleeping bruxism takes a secondary place as compared to COVID 19 treatment.

Therefore, the growth rate of the Sleeping Bruxism Treatment Industry has been moderate over the pandemic. However, the post-pandemic era seems promising for Sleeping Bruxism Treatment Market Growth.

Market Dynamics

Key drivers of the market 

As discussed earlier, the increased prevalence of sleep bruxism on a global scale is a major driver of the Market. According to an NCBI scientific study, the prevalence of Sleeping Bruxism borders on 12.5 percent. This figure is increasing day by day due to the increased usage of psychoactive substances and antidepressants. The prevalence increases the scope of application for the Market.  Another driver of the market is the increase in stress among people. In the busy pace of life and under a cloud of the pandemic, the Market has an opening for Sleeping Bruxism Treatment Market Growth.

Significant Opportunities

The COVID 19 pandemic and the post-pandemic phase is a period of significant opportunity for the Sleeping Bruxism Treatment Industry Size. The increased level of stress due to the COVID 19 pandemic has created an opportunity for Sleeping Bruxism treatment drugs. With the increased sale of the treatment drugs, the Sleeping Bruxism Treatment Market Size will increase by itself. However, there are some market restraints on which it has to function.

Market Restraints

The Sleeping Bruxism Treatment Market has certain restraints, such as the unavailability of treatment options. There is a lack of research and development in the Market that hinders its Sleeping Bruxism Treatment Industry Growth. The Market, therefore, has to focus more on developing more advanced treatment options. The key players of the Sleeping Bruxism Treatment Industry have to contribute to this for the future. Without research and development, the Market Growth will stagnate.

Market Challenges

The High cost of custom-fit night guards is also a market challenge that hiders the growth of the Sleeping Bruxism Treatment Market. Until and unless the cost of night guards reduces and aids the Sleeping Bruxism Treatment drugs in the application, the Sleeping Bruxism Treatment Industry will not see wholesome growth. The present effort is towards decreasing the impact of the high cost associated with night guards and sleeping bruxism treatment.

Cumulative Growth Analysis

Overall, the Sleeping Bruxism Treatment Industry Forecast shows that the Sleeping Bruxism Treatment Market Value will grow at a healthy rate of nearly 7 percent in the forecast period. The Market Value increases in the forecast period and will reach a valuation of nearly a trillion. The many drivers, opportunities, and Market trends will support the growth of the Sleeping Bruxism Treatment Market during the Market forecast period.

Segment Overview 

According to the Sleeping Bruxism Treatment Market Analysis, there are different segments of the Healthcare Consulting Services Market. The Sleeping Bruxism Treatment Market Share disperses over different segments according to type, diagnosis, treatment type, etc.

By type- By type, the treatment divides into primary bruxism and secondary bruxism.

By diagnosis- By diagnosis, the Market divides into clinical examination and polysomnography.

By treatment- By treatment, the Market Share divides into dental approaches and treatment drugs.

By cause – By cause, the Market the obstructive sleep apnea, GERD, malocclusion, and sleep paralysis.

By patient type- The Market divides into pediatric and adult based on patient classification.

Regional Overview 

By regions, the Sleeping Bruxism Treatment Market disperses over major regional markets of North America, Europe, and the Asia Pacific. According to the Sleeping Bruxism Treatment Market Outlook, the majority of the Market share belongs to the North American region. The Market trends point towards the European region becoming the fastest growing regional market for Sleeping Bruxism Treatment by 2028. The regional markets of the Asia Pacific and the Middle East will also register considerable growth due to the high population. However, the African regional market will show the lowest growth trend due to a lack of health awareness in the region.

Competitive Landscape

The Sleeping Bruxism Treatment market has different competitors who belong to different countries, the primary companies that dot the competitive landscape of the market are-

  • Ivoclar Vivadent AG

  • Ipsen Biopharmaceuticals, Inc.

  • Merz Pharma GmbH & Co. KGaA

  • Carestream Dental

  • Akervall Technologies Inc.


  • Randmark Dental Products, LLC

These competitors of the Sleeping Bruxism Treatment Industry belong to different nationalities and contribute to the market in various ways.

Recent Developments

  • In January 2019, Averall Technologies launched their SISU mouthguard against Sleep Bruxism and expanded their product portfolio in the USA.

Apart from this, the leading competitors of the market undertake mergers, acquisitions, and deals to improve their standing in the market. This profits the market in terms of Sleeping Bruxism Treatment Market trends of growth.

Report Overview 

The Sleeping Bruxism Treatment Market Outlook or overview is as follows:

  • Market Overview

  • COVID 19 Analysis

  • Market Dynamics

  • Segment Overview

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments

This report focuses on the Sleeping Bruxism Treatment Industry and its trends. It highlights the key drivers, significant opportunities for growth, and presents market challenges of the Sleeping Bruxism Treatment Industry. Thirdly, it discusses the segmentation of the Sleeping Bruxism Treatment Industry over various benchmarks and segments. Additionally, the Sleeping Bruxism Treatment Market Outlook sheds more light on the competitive landscape and recent developments of the market. It creates an overall reading of the Sleeping Bruxism Treatment Industry Forecast for the readers. 

Report Scope:
Report Attribute/Metric Details
  Market Size   USD 638.22 Million
  CAGR   2018-2023: 6.7%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment Type, Patient Type, End User and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Ivoclar Vivadent AG, Ipsen Biopharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, Carestream Dental, Akervall Technologies Inc., PLANMECA OY, Randmark Dental Products, LLC, S4S Dental Laboratory, Patterson Dental Supply, Inc., Henry Schein, Inc., and Pfizer Inc.
  Key Market Opportunities   Untapped Markets Of The Asia-Pacific Region
  Key Market Drivers

  • Increasing Prevalence Of Sleep Bruxism
  • Growing Child Population
  • Lifestyle Changes
  • Drivers Impact Analysis

  • Frequently Asked Questions (FAQ) :

    Sleeping bruxism treatment market projected to grow at approximately 6.7% CAGR during the assessment period (2020-2027).

    The valuation of the sleeping bruxism treatment market is estimated to increase to USD 638.2 MN by the end of 2023.

    Increasing prevalence of the disorder and growing funding & healthcare insurance coverage, are major tailwinds pushing the growth of the sleeping bruxism treatment market.

    North America holds the largest share in the sleeping bruxism treatment market, followed by Europe and the Asia Pacific, respectively.

    Ipsen Biopharmaceuticals, Inc., Pfizer Inc., Ivoclar Vivadent AG, Henry Schein, Inc., Merz Pharma GmbH & Co. KGaA, Carestream Dental, Patterson Dental Supply, Inc., S4S Dental Laboratory, Akervall Technologies Inc., PLANMECA OY, and Randmark Dental Products, LLC, are some of the top players operating in the global sleeping bruxism treatment market.

    Sleeping Bruxism Treatment – Summary

    The sleeping bruxism treatment market is expected to touch USD 638.22 million valuation by 2023, expanding at a modest CAGR of 6.7% during the forecast period (2018-2023), reports Market Research Future (MRFR). Sleeping bruxism is a disorder in which people grind or clench their teeth during sleep. This incident is quite natural. However, if the rate goes higher, it can damage the teeth or affect the jaw muscles.

    According to a study published by Sleep Research Society (SRS), generally 5-8% people suffer from this disorder resulting in tooth wear and headaches which inadvertently distresses their lifestyle. This can give rise to preventive measures such as anti-depressants, mouth guard, muscle relaxants, and others and provide a favorable condition for the market.

    Mayo Foundation’s report for the Medical Education and Research on sleeping bruxism reveals that the prevalence of bruxism among children varied from 3.5-40.6% and was seconded by the Journal of Conservative Dentistry. Both the reports suggested a hike in the number of affected children population. With the U.S. Census Bureau’s count of 74.7 million children by 2023, it has become even more disconcerting. This daunting number can drive the market further.  

    However, there is no specific cure for sleeping bruxism.  The available medications have side-effects which destabilize the physiological system. This could impede the market growth during the forecast period.


    The global market for sleeping bruxism treatment can be segmented by type, diagnosis, treatment, cause, patient, and end-user.

    By type, the market includes primary bruxism and secondary bruxism. Primary bruxism occurs without any medical condition, and mainly the clenching or grinding of teeth takes place. Currently, the predicted segment valuation is USD 168.74 million which it can achieve by 2023. Secondary bruxism is often triggered by neurological disorders or by psychoactive substance consumption. This segment accounted for 72.7 % of the global market share.

    Diagnosis-wise segmentation includes clinical examination, electromyographic methods, polysomnography, x-ray, and others. The disorder is not life-threatening but can result in dental problems making its early diagnosis necessary.

    Treatment-based segmentation includes dental approaches and medications. It’s not always necessary for children as they tend to outgrow it with age. However, severe cases demand treatment and the dental approaches segment could reach up to a significant valuation during the forecast period. Dental medication commanded around 68.6% of the global market in 2017.

    Based on cause, the market comprises obstructive sleep apnea, sleep paralysis, gastroesophageal reflux disease (GERD), malocclusion, and others. Reports of National Sleep Foundation reveals that one in four people suffer from obstructive sleep apnea which gives rise to sleeping bruxism. The market for obstructive sleep apnea is projected to reach USD 233.20 million at a 7% CAGR during the review period.

    Based on patient type, the market is segmented into pediatric and adult. According to KidsHealth, 3 out of 10 children suffer from bruxism. Pediatric segment currently dominates the market with 68.5% of the global share in 2017 and in the foreseeable future, is expected to do so by reaching USD 440.28 million mark with a CAGR of 6.8% during the prognosis period.

    The end-user segment includes hospitals, dental clinics, and others. With considerable technological advancements, hospitals and clinics now have ample provisions to take care of the situation. As the frontrunner, hospitals and clinics are projected to reach USD 270.50 million valuation during the review period.

    Regional Segmentation:

    Geographically the market covers the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

    The Americas dominated the market in 2017 by holding 39.1% of the market share. This is due to the rising cases of stress and anxiety related diseases among the populace. According to the American Sleep Association, 10% of the adults and 15% of the children are affected by the disease. Almost 8.3 million of the U.S. population are suffering from the disease as reported by the World Socialist Website in 2017. The market in the region, with an astounding 6.9% CAGR can reach USD 252.27 million by 2023.

    Europe is the second largest market where as per the European Orthodontic Society in 2014-2015 sleeping bruxism was prevalent in 14 to 20% of children, 8 to 12% of teenagers and 3% of the adult population. Obstructive sleep apnea syndrome is also a significant factor in the growth of this market as according to the reports of the European Lung Foundation, 3-7% male and 2-5% female suffer from the disease.

    APAC is expected to open up possibilities owing to its significant investment in healthcare, economic growth, large population base, and adoption of advanced healthcare technology. As per the reports of State of the World’s Children 2016, UNICEF, South Asia has 627 million children population, almost 36% of the total population and the number is on the rise giving the market a favorable condition. Also, bruxism and dental care related awareness are spreading rapidly in countries such as India, China, Japan and South Korea which can boost the market.

    Market Competition:

    APAC market is growing bigger day by day. According to the World Dental Show in 2017, the Indian dental market is expected to witness a staggering CAGR of 16% by the end of 2018 and reach USD 242.81 million valuation. In Australia, as per the reports of Snore Australia, 9% of women and 25% of men suffer from obstructive sleep apnea. This could also open up the market for further possibilities and also could lure in international players.

    The key players operating in the market are Randmark Dental Products, LLC, S4S Dental Laboratory, Ipsen Biopharmaceuticals, Inc., Pfizer Inc. Henry Schein, Inc., PLANMECA OY, Patterson Dental Supply, Inc., Merz Pharma GmbH & Co. KGaA, Ivoclar Vivadent AG, Carestream Dental, Akervall Technologies Inc., and others.

    Sleeping Bruxism Market: Competitive Landscape

    The sleeping bruxism treatment market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.

    The growth of the market vendors is dependent on the market conditions, government support, and industry development. Thus, the vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although the international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time to new products and increase the global market share.

    The vendors with better technical and financial resources can develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.

    Ipsen Biopharmaceuticals, Inc has a vast product portfolio in the sleeping bruxism treatment industry. The company also has a wide geographic presence as it operates in various countries across the world. They have a significant presence in North America, Europe, the Middle East & Africa, with commercial, manufacturing, and research facilities in more than one dozen countries.

    The top three manufacturers in the market are inclusive of:

    1. Randmark Dental Products, LLC

    2. S4S Dental Laboratory

    3. Ipsen Biopharmaceuticals, Inc.

    Randmark Dental Products, LLC has 70 years of experience in clinical dentistry and occlusal therapy. The company's line of business includes the manufacturing of dental night guards. The company’s NiteBite is patented and is an FDA-cleared device that functions within the patient's freeway space. The strengths of the company are inclusive of patented & FDA cleared devices and skilled workforce. The company is focused on product enhancements to enhance its customer base in the United States.

    S4S Dental Laboratory provides dental solutions such as occlusal splints that aids in the treatment of bruxism (facial pain, migraines, clenching, tooth wear, and TMJ dysfunction) and anti-snoring and sleep apnoea devices. The company complies with the requirements of DAMAS (Dental Appliance Manufacturers Audit Scheme) to enhance its quality management system. The company is focused on developing a wide range of products for dental and sleep-related breathing disorders. Moreover, the company’s focus is on building partnerships to provide holistic solutions.

    Ipsen Biopharmaceuticals, Inc. provides treatment for oncology, neuroscience, and rare diseases. It has two operating segments, namely, specialty care and consumer healthcare. The company focuses on developing innovative solutions to fulfill the customers’ needs. Innovative drugs and skilled workforce followed by a Strong R&D are the major factors strengthening the presence of the company in the market.